Abstract 238P
Background
Surgery remains the cornerstone of treatment in ovarian cancers with the aim to achieve a complete cytoreduction with no macroscopic residual disease. The present study tries to assess the feasibility of laparoscopic optimal cytoreduction surgery (LOCS) in patients with advanced ovarian cancer (AOC) with low burden disease.
Methods
A retrospective study of advanced ovarian cancer that underwent LOCS between 2010 and 2014 was done. Histologically confirmed epithelial or germ cell ovarian cancer who underwent either interval or primary cytoreduction surgery were included.
Results
In all 40 patients with stage 3 ovarian cancers were included in the analysis. The median age was 50 years and the median BMI was 23 kg/m2. 39 patients had epithelial ovarian cancer (38 – serous, 1- endometrioid) and 1 patient had germ cell tumor. 23 were grade 3 and 17 were grade 2, with no patient in grade 1. Stage wise majority were stage IIIC (26 patients) followed by 3 in stage IIIA and 1 patient was stage IIIB .3 patients underwent primary cytoreduction (1- IIIA, 2- IIIB) and 37 patients received neoadjuvant chemotherapy (NACT) before surgery. 3 to 8 cycles of chemotherapy was given. On the final histopathological examination, complete response was seen in 7 patients. There was no intraoperative complication and one postoperative complication (2.5%). The median time to discharge was 5 days and the median time to start chemotherapy was 23 days. After a median follow up of 70 months 7 patients (17.5%) were lost to follow up. The overall survival was 48.3% and the recurrence-free survival was 27.2 %.19 patients recurred in the peritoneum and 5 patients had a nodal recurrence.
Conclusions
Laparoscopic cytoreduction is feasible in patients with advanced-stage ovarian cancers, provided the disease burden permits optimal debulking, especially so if done in centers with experience in complex laparoscopic procedures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract